Top

Published in:

01-09-2015 | Clinical

New advances in genitourinary cancer: evidence gathered in 2014

Authors: C. Suárez, J. Puente, E. Gallardo, M. J. Méndez-Vidal, M. A. Climent, L. León, D. Olmos, X. García del Muro, E. González-Billalabeitia, E. Grande, J. Bellmunt, B. Mellado, P. Maroto, A. González del Alba

Published in: Cancer and Metastasis Reviews | Issue 3/2015

Abstract

This review provides updated information published in 2014 regarding advances and major achievements in genitourinary cancer. Sections include the best in prostate cancer, renal cancer, bladder cancer, and germ cell tumors. In the field of prostate cancer, data related to treatment approach of hormone-sensitive disease, castrate-resistant prostate cancer, mechanisms of resistance, new drugs, and molecular research are presented. In relation to renal cancer, relevant aspects in the treatment of advanced renal cell carcinoma, immunotherapy, and molecular research, including angiogenesis and von Hippel-Lindau gene, molecular biology of non-clear cell histologies, and epigenetics of clear renal cell cancer are described. New strategies in the management of muscle-invasive localized bladder cancer and metastatic disease are reported as well as salient findings of biomolecular research in urothelial cancer. Some approaches intended to improve outcomes in poor prognosis patients with metastatic germ cell cancer are also reported. Results of clinical trials in these areas are discussed.

Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians. doi:10.3322/caac.21208.

James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., De Bono, J. S., Gale, J., et al. (2014). Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology. doi:10.1016/j.eururo.2014.09.032.

Klotz, L., Miller, K., Crawford, E. D., Shore, N., Tombal, B., Karup, C., et al. (2014). Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. European Urology, 66, 1101–1108. doi:10.1016/j.eururo.2013.12.063.PubMedCrossRef

Crawford, E. D., Shore, N. D., Moul, J. W., Tombal, B., Schröder, F. H., Miller, K., et al. (2014). Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology, 83, 1122–1128. doi:10.1016/j.urology.2014.01.013.PubMedCrossRef

Garcia-Albeniz, X., Chan, J. M., Paciorek, A. T., Logan, R. W., Kenfield, S. A., Cooperberg, R. M., et al. (2014). Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. Journal of Clinical Oncology, 32, 5s (suppl; abstr 5003).CrossRef

Tombal, B., Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., et al. (2014). Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncology, 15, 592–600. doi:10.1016/S1470-2045(14)70129-9.PubMedCrossRef

Fizazi, K., Laplanche, A., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., et al. (2014). Docetaxel-estramustine in localized high-risk prostate cancer: results of the French Genito-Urinary Tumor Group GETUG 12 phase III trial. Journal of Clinical Oncology, 32, 5s (suppl; abstr 5005).CrossRef

Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., et al. (2014). Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature, 510, 278–282. doi:10.1038/nature13229.PubMedCentralPubMedCrossRef

Li, L., Chang, W., Yang, G., Ren, C., Park, S., Karantanos, T., et al. (2014). Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Science Signaling, 7, ra47. doi:10.1126/scisignal.2005070.PubMedCentralPubMedCrossRef

10.

Lohr, J. G., Adalsteinsson, V. A., Cibulskis, K., Choudhury, A. D., Rosenberg, M., Cruz-Gordillo, P., et al. (2014). Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature Biotcehnology, 32, 479–484. doi:10.1038/nbt.2892.CrossRef

11.

Carreira, S., Romanel, A., Goodall, J., Grist, E., Ferraldeschi, R., Miranda, S., et al. (2014). Tumor clone dynamics in lethal prostate cancer. Science Translational Medicine, 6, 254ra125. doi:10.1126/scitranslmed.3009448.PubMedCentralPubMedCrossRef

12.

Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., et al. (2014). Organoid cultures derived from patients with advanced prostate cancer. Cell, 159, 176–187. doi:10.1016/j.cell.2014.08.016.PubMedPubMedCentralCrossRef

13.

Castro, E., Goh, C., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Dadaev, T., et al. (2014). Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. European Urology. doi:10.1016/j.eururo.2014.10.022.PubMedCentral

14.

Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., et al. (2013). Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine, 369, 722–731. doi:10.1056/NEJMoa1303989.PubMedCrossRef

15.

Motzer, E. J., Hudson, T. E., McCann, L., & Choueiri, T. K. (2014). Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. New England Journal of Medicine, 370, 1769–1770. doi:10.1056/NEJMc1400731.PubMedCrossRef

16.

Rini, B. I., Bellmunt, J., Clancy, J., Wang, K., Niethammer, A. G., Hariharan, S., et al. (2014). Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology, 32, 752–759. doi:10.1200/JCO.2013.50.5305.PubMedCrossRef

17.

Motzer, R. J., Barrios, C. H., Kim, T. M., Falcon, S., Cosgriff, T., Harker, W. G., et al. (2014). Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 32, 2765–2772. doi:10.1200/JCO.2013.54.6911.PubMedCrossRef

18.

Michel, M.S., Vervenne, W., Santis, M., von Weikersthal, L.F., Goebell, P.J., Juergen Lerchenmueller, J., et al. (2014). SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology,32. (suppl 4; abstr 393).

19.

Hutson, T. E., Escudier, B., Esteban, E., Bjarnason, G. A., Lim, H. Y., Pittman, K. B., et al. (2014). Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 32, 760–767. doi:10.1200/JCO.2013.50.3961.PubMedCrossRef

20.

Motzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C., Zolnierek, J., et al. (2014). Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncology, 15, 286–296.

21.

Heng, D. Y., Wells, J. C., Rini, B. I., Beuselinck, B., Lee, J. L., Knox, J. J., et al. (2014). Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 66, 704–710. doi:10.1016/j.eururo.2014.05.034.PubMedCrossRef

22.

Tannir, N. M., Jonasch, E., Altinmakas, E., Ng, C. S., Qiao, W., Tamboli, P., et al. (2014). Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): a multicenter randomized phase 2 trial. Journal of Clinical Oncology, 32, 5s (suppl; abstr 4505).CrossRef

23.

A proof of concept study of maintenance therapy with tasquinimod in patients with metastatic castrate-resistant prostate cancer who are not progressing after a first line docetaxel based chemotherapy. Available at: http://clinicaltrials.gov/ct2/show/NCT01732549. Accessed June 6, 2014.

24.

Ojemuyinwa, M.A., Karzai, F.H., Shah, A.A., Theoret, M.R., Harold, N., Chun, G., et al. (2014). A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 32. (suppl; abstr 218).

25.

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J., et al. (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multi- centre, randomised, double-blind, phase 3 trial. Lancet Oncology, 15, 700–712. doi:10.1016/S1470-2045(14)70189-5.PubMedCrossRef

26.

Drake, C.G., Kwon, E.D., Fizazi, K., Bossi, A., van den Eertwegh, A.J., Logothetis, C. (2014). Results of subset analyses on overall survival (OS) from the study CA184-043: ipilimumab versus placebo in post-docetaxel metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 32. (suppl 4; abstr 2).

27.

Schweizer, M.T., Drake, C.G. (2014). Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Reviews: 33641–55.

28.

Miyahira, A. K., Kissick, H. T., Bishop, J. L., Takeda, E. Y., Barbieri, C. E., Simons, J. W., et al. (2014). Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden Prostate Cancer Academy meeting. Prostate, 75, 337–347. doi:10.1002/pros.22920.PubMedCrossRef

29.

Olson, B. M., Johnson, L. E., & McNeel, D. G. (2013). The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunology, Immunotherapy, 62, 585–596. doi:10.1007/s00262-012-1363-9.PubMedCentralPubMedCrossRef

30.

Lucas, J. M., Heinlein, C., Kim, T., Hernandez, S. A., Malik, M. S., True, L. D., et al. (2014). The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discovery, 4, 1310–1325. doi:10.1158/2159-8290.CD-13-1010.PubMedCentralPubMedCrossRef

31.

Theurillat, J. P., Udeshi, N. D., Errington, W. J., Svinkina, T., Baca, S. C., Pop, M., et al. (2014). Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science, 346, 85–89. doi:10.1126/science.1250255.PubMedCentralPubMedCrossRef

32.

Hussong, M., Börno, S. T., Kerick, M., Wunderlich, A., Franz, A., Sültmann, H., et al. (2014). The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response. Cell Death Diseases, 5, e1195. doi:10.1038/cddis.2014.157.CrossRef

33.

Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351, 1502–1512.PubMedCrossRef

34.

Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M. E., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine, 351, 1513–1520.PubMedCrossRef

35.

Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of Clinical Oncology, 26, 242–245. doi:10.1200/JCO.2007.12.4008.PubMedCrossRef

36.

Clarke, J. M., & Armstrong, A. J. (2013). Novel therapies for the treatment of advanced prostate cancer. Current Treatment Options in Oncology, 14, 109–126. doi:10.1007/s11864-012-0222-4.PubMedCentralPubMedCrossRef

37.

Sweeney, C., Chen, Y. H., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., et al. (2014). Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. Journal of Clinical Oncology, 32, 5s (suppl; abstr LBA2).CrossRef

38.

Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., et al. (2013). Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncology, 14, 149–158. doi:10.1016/S1470-2045(12)70560-0.PubMedCrossRef

39.

James, N. D., Sydes, M. R., Mason, M.D., et al. (2015). Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE. Journal of Clinical Oncology, 33. (suppl; abstr 5001)

40.

Dreicer, R., Jones, R., Oudard, S., Efstathiou, E., Saad, F., de Wit, R., et al. (2014). Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial). Journal of Clinical Oncology, 32. (suppl 4; abstr 7˄).

41.

de Wit, R., Fizazi, K., Jinga, V., Efstathiou, E., Fong, P., Wirth, M., et al. (2014). Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). Journal of Clinical Oncology, 32, 5s (suppl; abstr 5008).CrossRef

42.

Efstathiou, E. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). Available at: http://meetinglibrary.asco.org/content/94606

43.

Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367, 1187–1197.PubMedCrossRef

44.

Beer, T.M., Armstrong, A.J., Sternberg, C.N., Higano, C.S., Iversen, P., Loriot, Y., et al. (2014). Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study. Journal of Clinical Oncology, 32. (suppl 4; abstr LBA1^).

45.

Parker, C., Vogelzang, N. J., Sartor, A. O., Bottomley, D., Coleman, R. E., Skjorestad, I., et al. (2014). 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study. Journal of Clinical Oncology, 32, 5s (suppl; abstr 5070).CrossRef

46.

Ryan, C.J., Smith, M.R., Fizazi, K., Miller, K., Muders, P.F.A., Sternberg, C.N., et al. Final overall survival analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy. Available at: http://www.ascopost.com/ViewNews.aspx?nid=18643

47.

Zong, Y., & Goldstein, A. S. (2013). Adaptation or selection—mechanisms of castration-resistant prostate cancer. Nature Reviews. Urology, 10, 90–98. doi:10.1007/s11427-013-4522-0.PubMedCrossRef

48.

Karantanos, T., Evans, C. P., Tombal, B., Thompson, T. C., Montironi, R., & Isaacs, W. B. (2014). Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. European Urology. doi:10.1016/j.eururo.2014.09.049.PubMed

49.

Mills, I. G. (2014). Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nature Reviews Cancer, 14, 187–198. doi:10.1038/nrc3678.PubMedCrossRef

50.

Li, P., Yang, R., & Gao, W. Q. (2014). Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Molecular Cancer, 13, 55. doi:10.1186/1476-4598-13-55.PubMedCentralPubMedCrossRef

51.

Fleischmann, A., Rocha, C., Schobinger, S., Seiler, R., Wiese, B., & Thalmann, G. N. (2011). Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. Prostate, 71, 453–460. doi:10.1002/pros.21259.PubMedCrossRef

52.

Terry, S., & Beltran, H. (2014). The many faces of neuroendocrine differentiation in prostate cancer progression. Frontiers in Oncology, 4, 60. doi:10.3389/fonc.2014.00060.PubMedCentralPubMedCrossRef

53.

Efstathiou, E., Titus, M., Tsavachidou, D., Tzelepi, V., Wen, S., Hoang, A., et al. (2012). Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. Journal of Clinical Oncology, 30, 637–643. doi:10.1200/JCO.2010.33.7675.PubMedCentralPubMedCrossRef

54.

Efstathiou, E., Titus, M., Wen, S., Hoang, A., Karlou, M., Ashe, R., et al. (2015). Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. European Urology, 67, 53–60. doi:10.1016/j.eururo.2014.05.005.PubMedPubMedCentralCrossRef

55.

Rathkopf, D., & Scher, H. I. (2013). Androgen receptor antagonists in castration-resistant prostate cancer. Cancer Journal, 19, 43–49. doi:10.1097/PPO.0b013e318282635a.CrossRef

56.

Powell, K.A., Seeman, L., Maddipati, K.R., et al. (2014). ERG regulation of intracrine androgen production and castration-resistant prostate cancer progression [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5–9; San Diego, CA. Philadelphia (PA): AACR. Abstract nr 456.

57.

Mateo, J., Hall, E., Sandhu, S., Omlin, A.G., Miranda, S., Carreira, S., et al. (2014). Antitumour activity of the PARP inhibitor olaparib in unselected sporadic castration-resistant prostate cancer (CRPC) in the TOPARP trial. Annals of Oncology, 251–41. doi: 10.1093/annonc/mdu438.

58.

Conteduca, V., Salvi, S., Casadio, V., Burgio, S. L., Menna, C., Rossi, L., et al. (2014). AR and CYP17A1 copy number variations may predict clinical outcome of patients with metastatic castration-resistant prostate cancer treated with abiraterone. Annals of Oncology, 25(suppl 4), iv257–iv258. doi:10.1093/annonc/mdu336.7. Abstract 759PD.

59.

Bremmer, F., Jarry, H., Strauß, A., Behnes, C. L., Trojan, L., & Thelen, P. (2014). Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC). Springerplus, 3, 574. doi:10.1186/2193-1801-3-574. eCollection 2014.PubMedCentralPubMedCrossRef

60.

Wang, H. T., Yao, Y. H., Li, B. G., Tang, Y., Chang, J. W., & Zhang, J. (2014). Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis—a systematic review and pooled analysis. Journal of Clinical Oncology, 32(30), 3383–3390. doi:10.1200/JCO.2013.54.3553.PubMedCrossRef

61.

Small, E. J., Youngren, J., Alumkal, J., et al. (2014). Neuroendocrine prostate cancer (NEPC) in patients (pts) with metastatic castration resistant prostate cancer (MCRPC) resistant to abiraterone (ABI) or enzalutamide (ENZ): preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). Annals of Oncology, 25(suppl 4), iv258. doi:10.1093/annonc/mdu336.8. Abstract 760PD.

62.

Mulholland, D.J. (2014). Persistent androgen ablation promotes enhanced neuroendocrine features in Pten-deficient prostate cancer [abstract]. Proceeding of the American Association for Cancer Research; 2014 Apr 5–9; San Diego, CA. Philadelphia (PA): AACR. Abstract nr LB-44.

63.

Ware, K. E., Garcia-Blanco, M. A., Armstrong, A. J., & Dehm, S. M. (2014). Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocrine-Related Cancer, 21, T87–T103. doi:10.1158/1078-0432.CCR-13-1863.PubMedCentralPubMedCrossRef

64.

Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., et al. (2014). AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New England Journal of Medicine, 371, 1028–1038. doi:10.1056/NEJMoa1315815.PubMedCentralPubMedCrossRef

65.

Yu, Z., Chen, S., Sowalsky, A. G., Voznesensky, O. S., Mostaghel, E. A., Nelson, P. S., et al. (2014). Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical Cancer Research, 20, 1590–1600. doi:10.1158/1078-0432.CCR-13-1863.PubMedCentralPubMedCrossRef

66.

Arora, V. K., Schenkein, E., Murali, R., et al. (2013). Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell, 155, 1309–1322. doi:10.1016/j.cell.2013.11.012.PubMedCentralPubMedCrossRef

67.

Bishop, J. L., Sio, A., Angeles, A., Roberts, M. E., Azad, A. A., Chi, K. N., et al. (2015). PD-L1 is highly expressed in enzalutamide resistant prostate cancer. Oncotarget, 6, 232–242.CrossRef

68.

Nguyen, H. G., Yang, J. C., Kung, H. J., Shi, X. B., Tilki, D., Lara, P. N., Jr., et al. (2014). Targeting autophagy overcomes enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene, 33, 4521–4530. doi:10.1038/onc.2014.25.PubMedCentralPubMedCrossRef

69.

Chi, K. N., Higano, C., Reeves, J., Feyerabend, S., Gravis, G., Ferrero, J., et al. (2014). A randomized phase 3 study comparing first-line docetaxel/prednisone (DP) to DP plus custirsen in men with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 25(suppl 4), iv256. doi:10.1093/annonc/mdu336.3.

70.

Haas, N.B., Manola, J., Uzzo, R.G., Atkins, M.B., Wilding, G., Pins, M., et al. (2015) Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. Journal of Clinical Oncology, 33. (suppl 7; abstr 403).

71.

Melero, I., Grimaldi, A. M., Perez-Gracia, J. L., & Ascierto, P. A. (2013). Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Cancer Clinical Research, 29, 997–1008. doi:10.1158/1078-0432.CCR-12-2214.CrossRef

72.

Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity, 39, 1–10. doi:10.1016/j.immuni.2013.07.012.PubMedCrossRef

73.

Morse, M., McDermott, D. F., Daniels, G. A., Kaufman, H., Wong, M. K. K., Aung, S., et al. (2014). High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: extension of OS benefits beyond complete response (CR) and partial response (PR). Journal of Clinical Oncology, 32, 5s (suppl; abstr 4523).CrossRef

74.

Choueiri, T. K., Fishman, M. N., Escudier, B. J., Kim, J. J., Kluger, H. M., Stadler, W. M., et al. (2014). Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. Journal of Clinical Oncology, 32, 5s (suppl; abstr 5012).CrossRef

75.

Choueiri, T.K., Fishman, M.N., Escudier, B.J., Kim, J.J., Kluger, H.M., Stadler, W.M., et al. (2014). Exploratory study to investigate the immunomodulatory activity of nivolumab antibody in subjects with metastatic clear cell renal carcinoma (RCC) (CA209-009(NCT01358721. Annals of Oncology, 25. (suppl 4, abstr 1051).

76.

Motzer, R.J., Rini, B.I., McDermott, D.F., Redman, B.G., Kuzel, T.M., Harrison, M.R., et al. (2014). Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. Journal of Clinical Oncology.

77.

McDermott, D. F., Sznol, M., Sosman, J. A., Soria, J., Gordon, M. S., Hamid, O., et al. (2014). Immune correlates and long term follow up of a phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC). Annals of Oncology, 25(suppl_4), iv280–iv304. doi:10.1093/annonc/mdu337.

78.

Pardoll, D. M. (2012). The blockade of immune check-points in cancer immunotherapy. Nature Reviews Cancer, 12, 252–264.PubMedCrossRef

79.

Hammers, H., Plimack, E.R., Infante, J.R., Ernstoff, M.S., Rini, B.I., McDermott, D.F., et al. (2014). Phase I of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, 32. (Suppl 15s, abstr 4504).

80.

Amin, S., Plimack, E.R., Infante, J.R., Ernstoff, M.S., Rini, B.I., McDermott, D.F., et al. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, 32. (suppl, abstr 5010).

81.

Amin, S., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., et al. (2014). Nivolumab (N) (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib (S) or pazopanib (P) in patients (pts) with metastatic renal cell carcinoma (mRCC). Annals of Oncology, 25(suppl_4), iv361–iv372. doi:10.1093/annonc/mdu342.

82.

Choueri, T.K. (2014). Phase 1/2 study of pembrolizumab (MK-3475) in combination with pegylated interferon alfa-2b or ipilimumab in patients with advanced melanoma or renal cell carcinoma. Annals of Oncology, 25. (suppl 4, abstr 1075).

83.

McDermott, D. F., Infante, J. R., Voss, M. H., Motzer, R. J., Haanen, J. B. A. G., Chowdhury, S., et al. (2014). A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma. Journal of Clinical Oncology, 32, 5s (suppl; abstr TPS4604^).CrossRef

84.

Lieu, C., Bendell, J., Powderly, J. D., Pishvaian, M. J., Hochster, H., Eckhardt, S. G., et al. (2014). Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or chemotherapy (chemo) in patients (pts) with locally advanced or metastatic solid tumors. Annals of Oncology, 25(suppl_4), iv361–iv372. doi:10.1093/annonc/mdu342.

85.

Callahan, M. K., Ott, P. A., Odunsi, K., Bertolini, S. V., Pan, L. S., Venhaus, R. R., et al. (2014). A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. Journal of Clinical Oncology, 32, 5s (suppl; abstr TPS3120^).CrossRef

86.

Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Master, V. A., et al. (2014). Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib. Journal of Clinical Oncology, 32, 5s (suppl; abstr 4524^).CrossRef

87.

Khleif, S., Munn, D., Nyak-Kapoor, A., Mautino, M. R., Kennedy, E., Vahanian, N. V., et al. (2014). First-in-human phase 1 study of the novel indoleamine-2,3-dioxygenase (IDO) inhibitor NLG-919. Journal of Clinical Oncology, 32, 5s (suppl; abstr TPS3121).CrossRef

88.

Infante, J. R., Burris, H. A., III, Ansell, S. M., Nemunaltis, J. J., Weiss, G. R., Villalobos, V. M., et al. (2014). Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors. Journal of Clinical Oncology, 32, 5s (suppl; abstr 3027).CrossRef

89.

Bellmunt, J., Fougeray, R., Rosenberg, J. E., von der Maase, H., Schutz, F. A., Salhi, Y., et al. (2013). Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Annals of Oncology, 24, 1466–1472. doi:10.1093/annonc/mdt007.PubMedCrossRef

90.

Hagenkord, J. M., Gatalica, Z., Jonasch, E., & Monzon, F. A. (2011). Clinical genomics of renal epithelial tumors. Cancer Genetics, 204, 285–297. doi:10.1016/j.cancergen.2011.06.001.PubMedCrossRef

91.

Maher, E. R. (2013). Genomics and epigenomics of renal cell carcinoma. Seminars in Cancer Biology, 23, 10–17. doi:10.1016/j.semcancer.2012.06.003.PubMedCrossRef

92.

Cohen, H. T., & McGovern, F. J. (2005). Renal-cell carcinoma. New England Journal of Medicine, 353, 2477–2490.PubMedCrossRef

93.

Moserle, L., Jiménez-Valerio, G., & Casanovas, O. (2014). Antiangiogenic therapies: going beyond their limits. Cancer Discovery, 4, 31–41. doi:10.1158/2159-8290.CD-13-0199.PubMedCrossRef

94.

Jäger, W., Thomas, C., Fazli, L., Hurtado-Coll, A., Li, E., Janssen, C., et al. (2014). DHH is an independent prognosticator of oncologic outcome of clear cell renal cell carcinoma. Journal of Urology, 192, 1842–1848. doi:10.1016/j.juro.2014.07.013.PubMedCrossRef

95.

Miles, K. M., Seshadri, M., Ciamporcero, E., Adelaiye, R., Gillard, B., Sotomayor, P., et al. (2014). Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PLoS One, 9, e112371. doi:10.1371/journal.pone.0112371.PubMedCentralPubMedCrossRef

96.

Graham, D. K., DeRyckere, D., Davies, K. D., & Earp, H. S. (2014). The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nature Reviews Cancer, 14, 769–785.PubMedCrossRef

97.

Cancer Genome Atlas Research Network. (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499, 43–49. doi:10.1038/nature12222.CrossRef

98.

Li, S., Kong, Y., Si, L., Chi, Z., Cui, C., Sheng, X., & Guo, J. (2014). Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer, 14, 376. doi:10.1186/1471-2407-14-376.PubMedCentralPubMedCrossRef

99.

Kwiatkowski, D. J., & Manning, B. D. (2014). Molecular basis of giant cells in tuberous sclerosis complex. New England Journal of Medicine, 371, 778–780.PubMedCrossRef

100.

Pal, S. K., He, M., Tong, T., Wu, H., Liu, X., Lau, C., et al. (2014). RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Molecular Cancer Research. doi:10.1158/1541-7786.MCR-14-0352.

101.

Davis, C. F., Ricketts, C. J., Wang, M., Yang, L., Cherniack, A. D., Shen, H., et al. (2014). The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell, 26, 319–330. doi:10.1016/j.ccr.2014.07.014.PubMedCentralPubMedCrossRef

102.

Scelo, G., Riazalhosseini, Y., Greger, L., Letourneau, L., Gonzàlez-Porta, M., Wozniak, M. B., et al. (2014). Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nature Communications, 5, 5135. doi:10.1038/ncomms6135.PubMedCrossRef

103.

Brugarolas, J. (2014). Molecular genetics of clear-cell renal cell carcinoma. Journal of Clinical Oncology, 32, 1968–1976. doi:10.1200/JCO.2012.45.2003.PubMedCentralPubMedCrossRef

104.

Juengel, E., Nowaz, S., Makarevi, J., Natsheh, I., Werner, I., Nelson, K., et al. (2014). HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. Molecular Cancer, 13, 152. doi:10.1186/1476-4598-13-152.PubMedCentralPubMedCrossRef

105.

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine, 366, 883–889. doi:10.1056/NEJMoa1113205.PubMedCrossRef

106.

Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 481, 306–313. doi:10.1038/nature10762.PubMedCentralPubMedCrossRef

107.

Hiley, C. T., & Swanton, C. (2014). Spatial and temporal cancer evolution: causes and consequences of tumour diversity. Clinical Medicine, 14(Suppl 6), s33–s37. doi:10.7861/clinmedicine.14-6-s33.PubMedCrossRef

108.

Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., et al. (2014). Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics, 46, 225–233. doi:10.1038/ng.2891.PubMedPubMedCentralCrossRef

109.

Burrell, R. A., & Swanton, C. (2014). Tumour heterogeneity and the evolution of polyclonal drug resistance. Molecular Oncology, 8, 1095–1111. doi:10.1016/j.molonc.2014.06.005.PubMedCrossRef

110.

Gulati, S., Martinez, P., Joshi, T., Birkbak, N. J., Santos, C. R., Rowan, A. J., et al. (2014). Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. European Urology. doi:10.1016/j.eururo.2014.06.053.PubMedCentralPubMed

111.

Prior, C., Perez-Gracia, J. L., Garcia-Donas, J., Rodriguez-Antona, C., Guruceaga, E., Esteban, E., et al. (2014). Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One, 9, e86263. doi:10.1371/journal.pone.0086263.PubMedCentralPubMedCrossRef

112.

Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., et al. (2003). Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New England Journal of Medicine, 28, 859–866.CrossRef

113.

International Collaboration Trialists. (2011). International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long- term results of the BA06 30894 trial. Journal of Clinical Oncology, 29, 2171–2177.

114.

Petrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., Vavassori, I., & Barni, S. (2014). Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. European Urology, 65, 350–357.PubMedCrossRef

115.

Zargar, H., Espiritu, P. N., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., et al. (2014). Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. European Urology. doi:10.1016/j.eururo.2014.09.007.

116.

Choueiri, T. K., Jacobus, S., Bellmunt, J., Qu, A., Appleman, L. J., Tretter, C., et al. (2014). Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. Journal of Clinical Oncology, 32, 1889–1894. doi:10.1200/JCO.2013.52.4785.PubMedCrossRef

117.

Sternberg, C. N., Skoneczna, I. A., Kerst, J. M., Fossa, S. D., Albers, P., Agerbaek, M., et al. (2015). Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncology, 16, 76–86. doi:10.1016/S1470-2045(14)71160-X.PubMedCrossRef

118.

Leow, J. J., Martin-Doyle, W., Rajagopal, P. S., Patel, C. G., Anderson, E. M., Rothman, A. T., et al. (2014). Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. European Urology, 66, 42–54. doi:10.1016/j.eururo.2013.08.033.PubMedCrossRef

119.

Mak, R. H., Hunt, D., Shipley, W. U., Efstathiou, J. A., Tester, W. J., Hagan, M. P., et al. (2014). Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. Journal of Clinical Oncology, 32, 3801–3809. doi:10.1200/JCO.2014.57.5548.PubMedPubMedCentralCrossRef

120.

Castellano, D. E., Bellmunt, J., Maroto, J. P., Font-Pous, A., Morales-Barrera, R., Ghanem, I., et al. (2014). Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemotherapy and Pharmacology, 73, 857–867. doi:10.1007/s00280-014-2419-7.PubMedCrossRef

121.

Hoffman-Censits, J.H., Vaughn, D.J., Lin, J., Keefe, S.M., Haas, N.B. (2014). A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy. Journal of Clinical Oncology, 32. (suppl; abstr e15519).

122.

Alva, A., Daignault, S., Smith, D. C., & Hussain, M. (2014). Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma. Investigational New Drugs, 32, 188–194. doi:10.1007/s10637-013-0054-5.PubMedCrossRef

123.

De Santis, M., Wiechno, P. J., Lucas, C., Lin, C., Su, W., Bellmunt, J., et al. (2014). Mature survival (OS) data of a randomised international phase II trial (JASINT1): vinflunine (VFL) gemcitabine (GEM) vs. VFL-CBDCA in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC). Annals of Oncology, 25(suppl_4), iv280–iv304. doi:10.1093/annonc/mdu337.

124.

Hussain, M., Daignault, S., Agarwal, N., Grivas, P. D., Siefker-Radtke, A. O., Puzanov, I., et al. (2014). A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer, 120, 2684–2693. doi:10.1002/cncr.28767.PubMedCentralPubMedCrossRef

125.

Oudard, S., Culine, S., Vano, Y., Goldwasser, F., Théodore, C., Nguyen, T., et al. (2015). Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. European Journal of Cancer, 51, 45–54. doi:10.1016/j.ejca.2014.10.009.PubMedCrossRef

126.

Milowsky, M. I., Dittrich, C., Durán, I., Jagdev, S., Millard, F. E., Sweeney, C. J., et al. (2014). Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European Journal of Cancer, 50, 3145–3152. doi:10.1016/j.ejca.2014.10.013.PubMedCrossRef

127.

Kilgour, E., Ferry, D., Saggese, M., Arkenau, H. T., Rooney, C., Smith, N. R., et al. (2014). Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. Journal of Clinical Oncology, 32, 5 (suppl; abstr 11010).CrossRef

128.

Grivas, P. D., Daignault, S., Tagawa, S. T., Nanus, D. M., Stadler, W. M., Dreicer, R., et al. (2014). Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer, 120, 692–701. doi:10.1002/cncr.28477.PubMedCrossRef

129.

Krege, S., Rexer, H., von Dorp, F., de Geeter, P., Klotz, T., Retz, M., et al. (2014). Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU International, 113, 429–436. doi:10.1111/bju.12437.PubMedCrossRef

130.

Srinivas, S., Narayanan, S., Harshman, L.C., Lam, A.P., Vaishampayan, U.K., Haas, D., et al. Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer (UC). Journal of Clinical Oncology, 32. (suppl 4; abstr 299).

131.

Apolo, A.B..., Parnes, H.L., Madan, R.A., Gulley, J.L., Wright, J.J, Hoffman-Censits, J.H., et al. (2014). A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology, 32. (suppl 4; abstr 307).

132.

Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., et al. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 515, 558–562.PubMedCrossRef

133.

The Cancer Genome Atlas Research Network. (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315–322.PubMedCentralCrossRef

134.

Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., et al. (2013). Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. Journal of Clinical Oncology, 31, 3133–3140. doi:10.1200/JCO.2012.46.5740.PubMedCentralPubMedCrossRef

135.

Sjodahl, G., Lauss, M., Lovgren, K., Chebil, G., Gudjonsson, S., Veerla, S., et al. (2012). A molecular taxonomy for urothelial carcinoma. Clinical Cancer Research, 18, 3377–3386. doi:10.1158/1078-0432.CCR-12-0077-T.PubMedCrossRef

136.

Choi, W., Porten, S., Kim, S. H., Willis, D., Plimack, E. R., Hoffman-Censits, J., et al. (2014). Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell, 25, 152–165. doi:10.1016/j.ccr.2014.01.009.PubMedCentralPubMedCrossRef

137.

Damrauer, J. S., Hoadley, K. A., Chism, D. D., Fan, C., Tiganelli, C. J., Wobker, S. E., et al. (2014). Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings of the National Academy of Sciences of the United States of America, 111, 3110–3115. doi:10.1073/pnas.1318376111.PubMedCentralPubMedCrossRef

138.

Hussain, M. H., MacVicar, G. R., Petrylak, D. P., Dunn, R. L., Vaishampayan, U., Lara, P. N., Jr., et al. (2007). Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. Journal of Clinical Oncology, 25, 2218–2224.PubMedCrossRef

139.

Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B. (2002). Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Journal of Clinical Oncology, 20, 937–940.PubMedCrossRef

140.

Rebouissou, S., Bernard-Pierrot, I., de Reynies, A., Lepage, M. L., Krucker, C., Chapeaublanc, E., et al. (2014). EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science Translational Medicine, 6, 244ra291. doi:10.1126/scitranslmed.3008970.CrossRef

141.

Guo, G., Sun, X., Chen, C., Wu, S., Huang, P., Li, Z., et al. (2013). Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature Genetics, 45, 1459–1463. doi:10.1038/ng.2798.PubMedCrossRef

142.

Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., et al. (2012). Genome sequencing identifies a basis for everolimus sensitivity. Science, 338, 221. doi:10.1126/science.1226344.PubMedCentralPubMedCrossRef

143.

Wagle, N., Grabiner, B. C., Van Allen, E. M., Hodis, E., Jacobus, S., Supko, J. G., et al. (2014). Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discovery, 4, 546–553.PubMedCentralPubMedCrossRef

144.

Gui, Y., Guo, G., Huang, Y., Hu, X., Tang, A., Gao, S., et al. (2011). Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genetics, 43, 875–878. doi:10.1038/ng.907.PubMedCrossRef

145.

Lehmann, A. R. (2001). The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes and Development, 15, 15–23.PubMedCrossRef

146.

Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., et al. (2014). Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discovery, 4, 1140–1153. doi:10.1158/2159-8290.CD-14-0623.PubMedCentralPubMedCrossRef

147.

Blaveri, E., Simko, J. P., Korkola, J. E., Brewer, J. L., Baehner, F., Mehta, K., et al. (2005). Bladder cancer outcome and subtype classification by gene expression. Clinical Cancer Research, 11, 4044–4055.PubMedCrossRef

148.

Powles, T. N. J. V., Fine, G. D., Eder, J. P., Braiteh, F. S., Loriot, Y., & Zambrano, C. Z. (2014). Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). Journal of Clinical Oncology, 32, 5s (suppl; abstr 5011)CrossRef

149.

International Germ Cell Cancer Collaborative Group. (1997). International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. Journal of Clinical Oncology, 15, 594–603.

150.

Einhorn, L. H., Williams, S. D., Loehrer, P. J., Birch, R., Drasga, R., Omura, G., et al. (1989). Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. Journal of Clinical Oncology, 7, 387–391.PubMed

151.

Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., et al. (2005). Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of Clinical Oncology, 23, 6549–6555.PubMedCrossRef

152.

Motzer, R. J., Nichols, C. J., Margolin, K. A., Bacik, J., Richardson, P. G., Vogelzang, N. J., et al. (2007). Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Journal of Clinical Oncology, 25, 247–256.PubMedCrossRef

153.

Daugaard, G., Skoneczna, I., Aass, N., De Wit, R., De Santis, M., Dumez, H., et al. (2011). A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Annals of Oncology, 22, 1054.61. doi:10.1093/annonc/mdq575.PubMedCrossRef

154.

Fizazi, K., Culine, S., Kramar, A., Amato, R. J., Bouzy, J., Chen, I., et al. (2004). Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. Journal of Clinical Oncology, 22, 3868–3876.PubMedCrossRef

155.

Massard, C., Kramar, A., Beyer, J., Hartmann, J. T., Lorch, A., Pico, J. L., et al. (2013). Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Annals of Oncology, 24, 322–328. doi:10.1093/annonc/mds504.PubMedCrossRef

156.

Fizazi, K., Pagliaro, L.C., Flechon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., et al. (2013). A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: results of GETUG 13. Journal of Clinical Oncology, 31. (suppl; abstr LBA4500).

Title: New advances in genitourinary cancer: evidence gathered in 2014
Authors: C. Suárez
J. Puente
E. Gallardo
M. J. Méndez-Vidal
M. A. Climent
L. León
D. Olmos
X. García del Muro
E. González-Billalabeitia
E. Grande
J. Bellmunt
B. Mellado
P. Maroto
A. González del Alba
Publication date: 01-09-2015
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-015-9577-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials

Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC Guide to design and report trials

Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma

Revisit dietary fiber on colorectal cancer: butyrate and its role on prevention and treatment

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis

The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer